BOULDER, Colo., Jan. 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, February 6, 2018. Ron Squarer, Chief Executive Officer, will lead the call.
Date:
Tuesday, February 6, 2018
Time:
9:00 a.m. Eastern Time
Toll-Free:
(844) 464-3927
Toll:
(765) 507-2598
Pass Code:
6187887
Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/gwxnqcbs
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com
View original content with multimedia: http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2018-on-february-6-2018-300589831.html
SOURCE Array BioPharma Inc.